ACOG Menopause Guidelines 2026: What Changed, What to Ask

If a doctor once told you hormones were too risky to consider, you are not imagining the shift. The ACOG menopause guidelines were rewritten in October 2026. The new advice sounds very different from what many of us heard for years.

Here’s the short version. Hormones are back as a strong first choice for hot flushes and the sleep problems they cause. Two newer non-hormonal drugs are now strongly backed too. Meanwhile, the old blanket fear that kept a whole generation away from care no longer matches the data.

Below, we walk through what changed, what didn’t, and what to ask at your next visit.

What the ACOG Menopause Guidelines Actually Changed

ACOG — the American College of Obstetricians and Gynecologists — published Clinical Practice Guideline No. 13 on October 15, 2026. It replaces a bulletin from January 2014. That is a twelve-year gap. For the wider shift, see our guide to the 2026 menopause treatment guidelines.

The ACOG menopause guidelines cover three symptom areas: hot flushes, sleep, and mood. ACOG calls this its most complete menopause guidance to date. That wording matters. It means each option now carries a grade.

Why does this feel like news? Because a big piece of the story landed eight months earlier. On February 12, 2026, the FDA approved new labels for six hormone products. It removed the boxed warnings for heart disease, breast cancer, and probable dementia.

Those warnings shaped two decades of cautious prescribing. Now the official US label says something else. That is why the ACOG menopause guidelines read the way they do.

One number puts this in perspective. In 2020, about 41 million US women were between 45 and 64. Only about 2 million women aged 46 to 65 filled a hormone prescription.

That gap is why ACOG’s president, Dr. Camille Clare, called access to evidence-based care “critically important” as menopause misinformation continues to flourish. Read the full ACOG announcement on expanded menopause guidance and you’ll see that concern repeated.

Hormones Are Still the Strongest Option

Let’s be clear about what “strong” means in the ACOG menopause guidelines. ACOG uses two labels. “ACOG recommends” signals a strong call. The benefits clearly outweigh the harms for most people. “ACOG suggests” signals a softer one. There, the balance depends on your own situation.

Hormones earned the strong label for hot flushes and for sleep problems caused by them. If you have a uterus, you take estrogen plus a progestogen. The progestogen protects your uterine lining. If you don’t have a uterus, estrogen alone is enough.

One small note on wording. ACOG prefers “hot flushes” to “hot flashes.” The sensation usually lasts one to five minutes. It is not momentary.

The Effect Is Not Subtle

A review cited in the guidance found estrogen, with or without a progestogen, cut how often hot flushes happened by more than half. It cut how severe they felt by more than two-thirds.

Here is a distinction worth knowing. Among the options ACOG recommends, estrogen-containing therapy is the only one shown to reduce both how often hot flushes happen and how severe they feel. The same 2026 review found that oxybutynin also reduced both — but ACOG does not recommend it as a primary option. Its side effects include cognitive decline in women over 65. A conjugated estrogen plus bazedoxifene combination also reduced both. ACOG conditionally suggests it as an alternative to standard estrogen-progestogen therapy.

The newer non-hormonal drugs work in a narrower way. A 2026 systematic review for the American College of Physicians found that the newer non-hormonal drugs reduce frequency but not severity.

The Timing Window, in Plain Terms

Timing carries real weight in the ACOG menopause guidelines. Start before age 60, or within 10 years of menopause. A review of 19 trials with more than 40,000 women backs this up. Starting inside that window was linked to lower heart disease risk.

Starting later is a different math problem. More than 10 years past menopause, the data show higher risks of blood clots and stroke. That does not mean never. It means a longer, more careful talk.

The Numbers Behind the Fear

Now for the figures that rarely make headlines. In the Women’s Health Initiative trials, over a median of 5.6 years of follow-up, combined therapy was linked to about 5 extra strokes, 10 extra blood clots, and 5 extra cases of invasive breast cancer per 1,000 women.

Estrogen alone showed no rise in breast cancer risk. It was linked to roughly 8 extra strokes and 5 extra clots per 1,000 women.

Put another way: most women in those trials had no event at all. Nearly 67 percent of the participants were 60 or older. So a woman in her early fifties is not well represented in the data those warnings came from.

Patches, Gels, or Pills?

Route is worth raising. A network meta-analysis of 32 trials ranked transdermal estradiol plus a progestogen as most effective for cutting hot flush frequency. “Transdermal” simply means a patch, gel, or spray rather than a pill.

However, that same 2026 review for the American College of Physicians found dose mattered more than route for symptom relief. So don’t assume one form is better.

On the flip side, route may matter for safety. Some analyses suggest transdermal estrogen carries a lower clot risk than oral. If you have migraine, obesity, or a clot risk factor, that is a fair question to ask.

One practical detail worth raising: if you take levothyroxine for your thyroid, ask whether your hormone route could affect your dose. Some clinicians check thyroid levels within a few months of starting, stopping, or switching treatment.

If You Can’t or Don’t Want Hormones

Maybe you have had breast cancer. Maybe you have had a stroke or a clot. Maybe you simply don’t want hormones. Under the ACOG menopause guidelines, you have far more options than you did in 2014.

Two newer drugs now carry a strong call. They are called neurokinin receptor antagonists — a mouthful, so let’s shorten it to NK drugs. Instead of replacing estrogen, they block a brain signal involved in temperature control.

Fezolinetant (Veozah) and elinzanetant (Lynkuet) are both once-daily oral tablets; your prescriber will confirm your dose. Both cut hot flushes. A 2026 meta-analysis in Menopause covering seven trials and more than 3,000 women found meaningful improvement in how sleep problems felt to women taking them. Two caveats worth knowing: the outcome was patient-reported rather than measured in a sleep lab, and the review rated the certainty of that evidence low because results varied substantially between trials. Treat it as a promising signal, not a guarantee.

Antidepressant drugs are the other strong option. SSRIs and SNRIs cut hot flushes in trials, even in people who were not depressed. Only one is FDA-approved for hot flushes: paroxetine at 7.5 mg daily. Others, such as escitalopram and venlafaxine, are used off-label.

Here is a safety point that matters. If you take tamoxifen for breast cancer, fluoxetine and paroxetine should usually be avoided. They interfere with how your body converts tamoxifen into its active form. Ask about escitalopram or venlafaxine instead.

Gabapentin sits lower on the list. It is sedating, so most people take it at bedtime. In pooled trials it cut hot flushes by about 2.8 a day, though it did not clearly reduce how severe they felt. ACOG suggests it when other non-hormonal options fail or cause side effects.

When Mood Is the Main Symptom

The ACOG menopause guidelines also say something practical about mood. The group found the evidence too thin to recommend hormones just for menopause-related depression. If low mood is your main symptom, the guidance sends you toward depression care instead.

Still, there is a neat overlap. SSRIs and SNRIs treat hot flushes and depression at the same time. If you have both, that dual benefit is worth asking about.

The Supplement Question: What the Guidance Really Says

This is where readers get the most confused. Walk into any pharmacy and you’ll find shelves of “menopause support” products. The ACOG menopause guidelines reviewed the evidence and did not back them.

The advice is blunt. Evidence does not support the safety or efficacy of phytoestrogens, such as soy isoflavones, or herbal supplements for hot flushes. There is also a practical problem. These products are not checked by the FDA before they reach the shelf. Nobody has tested them for purity or dose.

However, “not recommended” is not the same as “proven useless.” A 2019 overview of 29 systematic reviews found low-certainty signals for soy isoflavones, genistein, and combined black cohosh. The certainty of that evidence was not high.

So what do you do with that? Here is the practical middle path.

• Food is not a supplement. Edamame, tempeh, tofu, and soy milk are plain foods. A concentrated isoflavone pill is a drug-like dose with no oversight.
• Be careful with black cohosh. Case reports have linked it to liver injury. If you have liver disease, skip it.
• Tell your clinician everything. Herbal products can interact with prescription drugs. Nobody will ask unless you speak up.

Non-Drug Options: What They Really Do

The ACOG menopause guidelines suggest five non-drug approaches. They are CBT, mindfulness, exercise, clinical hypnosis, and acupuncture. “Suggest” means the evidence is supportive but not as strong.

Here’s the nuance almost nobody explains. These approaches work differently than drugs do. A 2026 review in BMC Women’s Health pooled 28 trials and nearly 2,900 women. It found medium-to-large drops in how bothersome hot flushes and night sweats felt. The effect on how many you get was smaller.

Sleep is where they shine. That same review found real gains in sleep quality and insomnia. This matters, because poor sleep is often the symptom women rate as most intolerable.

CBT deserves its own mention. It is structured and skills-based. One tested version is an eight-session group program; other programs differ in length and format, and the research reviews note that the dose varies a lot between studies. A 2026 randomized trial of group CBT found it cut hot flush distress and daily interference, and improved quality of life and anxiety.

Be realistic about the limits, though. In that same trial, sleep gains did not hold at follow-up, and depressive symptoms did not change. CBT delivered for hot flushes is not a treatment for depression. If low mood is your main symptom, that needs depression-focused care — which may itself include a different course of CBT, or an SSRI or SNRI that also happens to help hot flushes.

Exercise and mindfulness carry the best sleep evidence of the group. ACOG notes that hypnosis and acupuncture evidence is thinner. Acupuncture trials were mostly small, run in China, and mixed against sham treatment. Both are low-risk, so they are fair additions rather than replacements.

How to Use the ACOG Menopause Guidelines at Your Appointment

The ACOG menopause guidelines only help if you use them. Knowledge changes nothing until it changes the talk in the exam room.

First, track for two or three weeks. Note how often symptoms happen, how intense they are, and how they affect your sleep and work. Also note any change in your period’s length or flow.

Second, write down your history. Heart disease, stroke, blood clots, and breast cancer in you or your family all change the math. Bring that list even if you think they already have it.

That last question matters more than it sounds. ACOG stresses personal decisions and ongoing risk review. Many clinicians schedule a follow-up within two to three months of starting treatment, which is one practical way to make that ongoing review happen. Ask for a date before you leave the office.

Already Past 60? Here’s the Conversation to Have

This is the part headlines skip. What if you are 63, you never took hormones, and you are reading this wondering whether the door closed?

Here is the honest answer. The ACOG menopause guidelines recommend starting before 60 or within 10 years of menopause. They do not forbid treatment after that. They say the balance of benefit and risk shifts.

So ask the question anyway. A clinician should weigh your symptoms, your history, and your own goals. Sometimes the answer is still yes. Sometimes it is a non-hormonal drug or a therapy program.

Either way, you have options. Hot flushes do not become untreatable at 61.

Frequently Asked Questions

The Bottom Line

Menopause is normal. Struggling through it is optional. That is basically ACOG’s message, and it took twelve years to say it this clearly.

The ACOG menopause guidelines did not discover a miracle. They caught up with evidence that had been building for two decades. Hormones work well when started in the right window. The newer non-hormonal drugs are real options. Mind-body support helps more with distress and sleep than with hot flush counts. Supplements remain unproven and unchecked.

Your next step is small and concrete. Write down your top three symptoms. Note your family history. Print the ten questions above. Then book the visit you have been putting off.

You do not have to figure this out from headlines. You just need the right questions and a clinician willing to have the talk.

This article is for general information and is not a substitute for individual medical advice. Menopause care depends on your own health history and should be discussed with a qualified clinician. This article is flagged for medical review before final sign-off.